While the use of mutated p53 as a tumor antigen for therapeutic vaccines requires personalized preparations, limiting its practical feasibility, the wild-type p53 epitopes can be used effectively to induce the ASIR (similar to other TSAs), as most tumors with loss of function of p53 tend to overexpress p53 [123]. The gene discussed is TP53; the disease is neoplasm.